SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
Lancet Diabetes Endocrinol · 2019
Last updated 2026-05-28| Journal | Lancet Diabetes Endocrinol, 2019 |
|---|---|
| Citations | 8 |
| Relative citation ratio | 0.34 |
| NIH percentile | 21 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Full record and abstract on PubMed 31540866 ↗